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NEUROPSYCHOLOGY
Testosterone biases the amygdala toward
social threat approach
Sina Radke,1,2,3* Inge Volman,1,4,5 Pranjal Mehta,6 Veerle van Son,1 Dorien Enter,4,7
Alan Sanfey,1,4 Ivan Toni,1 Ellen R. A. de Bruijn,7 Karin Roelofs1,4
Testosterone enhances amygdala reactions to social threat, but it remains unclear whether this neuroendocrine
mechanism is relevant for understanding its dominance-enhancing properties; namely, whether testosterone
biases the human amygdala toward threat approach. This pharmacological functional magnetic-resonance im-
aging study shows that testosterone administration increases amygdala responses in healthy women during
threat approach and decreases it during threat avoidance. These findings support and extend motivational
salience models by offering a neuroendocrine mechanism of motivation-specific amygdala tuning.
INTRODUCTION
Testosterone lies at the core of social interactions by facilitating social
approach and dominance-seeking behavior across species (1, 2). In
humans, testosterone administration leads to enhanced amygdala re-
activity to angry faces. This effect has traditionally been interpreted as
reflecting increased vigilance to social threat, and potentially resulting
in increased aggression (3–6). However, threat vigilance can prime di-
vergent motivational reactions, namely, threat approach, but also
threat avoidance. Threat approach has been theoretically and empiri-
cally linked to social dominance, whereas threat avoidance is a clear sign
of social submissiveness (1, 7–9). In line with this, recent motivational
salience theories predict that increased amygdala activity does not
reflect emotional salience but is rather a function of motivational
salience (10, 11).
Therefore, to facilitate adaptive responding, testosterone should
modulate amygdala activity on the basis of the motivational context—
and not the emotional context per se. More precisely, approach-enhancing
effects of testosterone during social challenges (12–14) should be sup-
ported by enhanced amygdala reactivity during motivational approach
and not during avoidance. We tested this hypothesis using a double-
blind, randomized, placebo-controlled testosterone administration study,
combining functional magnetic resonance imaging (fMRI) with a well-
established social approach-avoidance (AA) task in which angry and
happy faces have to be approached or avoided by pulling or pushing a
joystick, respectively (15, 16).
During the AA task, a discrepancy between task instructions and
automatic action tendencies of avoiding angry and approaching happy
faces leads to increased activation of the anterior prefrontal cortex
(aPFC), which coordinates the contribution of several brain regions,
including the amygdala (15–17). In particular, the aPFC down-regulates
amygdala responses when the internally driven emotional response
tendencies need to be controlled according to externally driven task
instructions.
Here, we tested for motivation-specific effects of testosterone on
amygdala function. A single dose of 0.5 mg of testosterone or placebo
was administered to 54 healthy females 4 hours before acquiring fMRI
measurements. This procedure has been extensively validated in pre-
vious social affective neuroscience research (4, 12, 18, 19). Here, sali-
vary testosterone levels were increased when functional data were
obtained (see Table 1).
RESULTS
As expected on the basis of motivational salience accounts (10, 11),
motivation-specific effects in the amygdala were modulated by testos-
terone. Namely, there was increased activation in the right amygdala
during threat approach after testosterone administration [Substance
(testosterone > placebo) × Emotion (angry > happy) × Movement (ap-
proach > avoid) interaction; region of interest (ROI) analysis: coordi-
nates, 32 −2 −16; z value = 3.63; PFWE (P value with family-wise error
correction) = 0.043]. Analyses involving the reversed Emotion contrast
(that is, happy > angry) did not yield significant amygdala activation.
Post hoc testing confirmed that the motivation effect was specific for
angry faces (Fig. 1; Substance × Movement interaction: F1,52 = 8.58, P =
0.005, partial h2 = 0.14). Compared to placebo, testosterone administra-
tion increased amygdala activity during approach trials (F1,52 = 6.06, P =
0.017, partial h2 = 0.10) but decreased it during avoidance trials (F1,52 =
8.68, P = 0.005, partial h2 = 0.14). In addition, amygdala activity sig-
nificantly differed between approach and avoidance of angry faces after
testosterone administration (F1,25 = 6.33, P = 0.019, partial h
2 = 0.20) but
not after placebo (F1,27 = 2.86, P = 0.10, partial h
2 = 0.09). A similar pat-
tern of activation was also present at an uncorrected threshold within a
left amygdala cluster (coordinates, −32 −8 −18; z value = 2.58; Puncorr =
0.005; see Supplementary Methods and Results).
The activity of the aPFC was increased during incongruent com-
pared to congruent responses (Emotion × Movement interaction:
coordinates of local maxima, 30 62 −4; z value = 4.30; PFWE = 0.03;
see Fig. 2), additionally corroborating the robustness of this task, re-
plicating previous findings (15–17). These cerebral congruency effects
were present under both substances (for placebo: coordinates of local
maxima, 26 54 18; z value = 4.36; PFWE = 0.024; for testosterone:
coordinates of local maxima, 30 64 −4; z value = 4.64; PFWE = 0.008,
respectively). Testing for differential effects of cerebral congruency,
that is, interactions between substance and congruency, yielded
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no significant effects in the aPFC. Similarly, there were no testosterone-
dependent changes in connectivity between the amygdala and the right
aPFC during incongruent compared to congruent responses (PFWE <
0.05, seed at right aPFC cluster). Together, these results indicate that the
between-group differences in amygdala responses are not due to dis-
similar aPFC involvement.
Behaviorally, the social AA task elicited faster approach move-
ments to happy faces and avoidance movements to angry faces (con-
gruent reactions) than when the opposite, incongruent movements
needed to be executed [Emotion × Movement interaction in the repeated-
measures analysis of variance (ANOVA) on the reaction times (RTs): F1,50 =
28.91, P < 0.001, partial h2 = 0.36; see Table 2 for means]. There was
an additional main effect of Movement (F1,50 = 29.16, P < 0.001, partial
h2 = 0.36) being due to faster approach (mean, 684.08; SD, 130.88) than
avoidance movements (mean, 707.78; SD, 132.69), as previously re-
ported with this joystick (17). None of the substance-related effects were
significant (all F ’s < 2.9 and P’s > 0.09), indicating well-matched task
performance across substance groups.
DISCUSSION
This pharmacological fMRI study offers causal evidence that testos-
terone modulates the amygdala in a motivation-specific manner. Our
findings indicate that increased amygdala activity after testosterone
administration is bound to social threat approach. Previous studies re-
ported preferential processing of threat after testosterone administration
during passive viewing or matching of faces (3–6). By differentiating
between approach and avoidance, we showed that testosterone mod-
ulates amygdala reactivity according to current motivational demands
and not according to the emotional or action context per se. This
motivation-specific mechanism converges with approach-enhancing
effects of testosterone observed during social challenges (12–14).
The present study advances recent motivational salience models
(10, 11) by providing evidence for a neuroendocrine mechanism in
which testosterone biases the organism toward threat approach and
away from threat avoidance by modulating amygdala responses. This
enhances our understanding of the processes by which testosterone
primes the individual for defense of its status in social challenges. Acti-
vational effects of testosterone, such as increased vigilance and up-
regulation of neural circuits mediating aggression (3–6), inhibition of
fear responses (18), and facilitated threat approach (12), further con-
tribute to adaptive responding. In competitive interactions, testosterone
has been shown to promote status not only by means of overt aggres-
sion but also by more subtle dominance displays, such as increased
reciprocity (20, 21).
Table 1. Means (SE) of salivary hormone levels. P values indicate
differences between substance groups. For cortisol, there was only a
general effect of time, that is, decreasing cortisol levels in the course
of the experiment.
Placebo Testosterone P value
Testosterone levels (pg/ml)
At baseline 22.2 (2.8) 23.6 (3.0) 0.74
3 hours after administration 15.2 (2.0) 1361.4 (290.1) <0.001
5 hours after administration 21.4 (2.4) 450.2 (78.8) <0.001
Cortisol levels (nM)
At baseline 16.7 (2.4) 14.5 (1.2) 0.42
3 hours after administration 6.6 (1.2) 5.3 (0.4) 0.32
5 hours after administration 6.1 (0.5) 5.8 (0.4) 0.62
Fig. 2. Across-group aPFC activity (local maxima, 30 62 −4) for moti-
vationally incongruent versus congruent trials within Brodmann area 10.
The image is thresholded at P < 0.05 (uncorrected) for visualization purposes.
No other clusters reached significance for the comparison between in-
congruent and congruent responses in the whole group (that is, none
reached whole-brain FWE correction). aPFC activity did not differ between
substance groups.
Table 2. Means (SE) of RTs during the social AA task in milliseconds.
P values indicate differences between substance groups.
Placebo Testosterone P value
Happy approach 676 (29) 655 (19) 0.55
Happy avoid 745 (29) 692 (22) 0.16
Angry approach 723 (29) 683 (23) 0.30
Angry avoid 713 (29) 680 (20) 0.36
Fig. 1. Amygdala reactivity (localmaxima, 32 −2 −16) showingmotivation-
specific effects of testosterone during threat approach and avoidance. (A)
Enhanced activation for approach versus avoidance of angry faces after tes-
tosterone administration compared to placebo. The image is thresholded
at P < 0.05 (uncorrected) for visualization purposes. Note that a cluster of
activation showing a similar pattern is also present at uncorrected thresh-
old within the left amygdala (coordinates, −32 −8 −18; z value = 2.58;
Puncorr = 0.005; see fig. S1). (B) Contrast estimates for right amygdala cluster
during approach and avoidance of angry faces in each condition. Error bars
represent SEM. *P < 0.05, **P < 0.01.
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The motivation-specific effects of testosterone on amygdala tuning
were not complemented by behavioral changes, as previously obtained
outside a scanner with a more salient AA task (12). Building on an
extensive line of research applying the current AA task (15–17), we
used a relatively mild task version that is particularly sensitive to iso-
late neural effects. In line with previous fMRI studies (15–17), we only
found effects on the neural level with task performance being well
matched across substance groups. Therefore, we can conclude that
the testosterone-induced bias of the amygdala toward threat approach
is not due to a neural consequence of behavioral differences.
Alternatively, approaching threat might be perceived as “congru-
ent” after testosterone administration, so that internally driven emo-
tional response tendencies and externally driven task instructions
overlap. However, in the current study, there was not a reversal in the
direction of behavioral congruency effects after testosterone administra-
tion. Moreover, if approaching became more pleasant after testosterone
administration, the amygdala activation would reflect a main effect of
action direction. No such effect was observed (PFWE < 0.05). This
supports our finding that the amygdala effects result from the inter-
action between stimulus valence and action direction.
Our findings may have direct treatment implications for individ-
uals suffering from dysregulations of social AA such as patients with
anxiety disorders or depression (9). Lower testosterone levels were ob-
served in patients with social anxiety disorder, patients with general-
ized anxiety disorder, and patients with depression (22). The notion that
external administration of hormones might compensate for low endog-
enous testosterone levels and social affective symptoms associated with
it remains to be investigated in clinical research.
MATERIALS AND METHODS
Study design
Subjects. Fifty-four female volunteers (mean age, 21.6; SD, 2.4;
range, 18 to 30) were enrolled for participation. Exclusion criteria were
history of endocrine, neurological or psychiatric disorder, left-hand
dominance, uncorrected vision, habitual smoking, use of medication
or drugs (except for paracetamol and contraceptives), current paro-
dontitis, pregnancy or breast-feeding, and irregular sleep patterns.
All participants were using hormonal contraceptives to control for
changes in endocrine levels over the menstrual cycle. Testosterone-
and placebo-treated subjects did not differ with respect to their per-
sonality traits (see table S1). The participants were asked to abstain
from alcohol and nicotine 24 hours before testing and received a stan-
dardized light lunch on the day of testing. Written informed consent was
obtained from all the participants, and the study protocol was approved
by the CommissieMensgebondenOnderzoek (CMO)Nijmegen-Arnhem
in accordance with the declaration of Helsinki. All participants received
financial compensation.
Substance administration and procedure. In a double-blind, ran-
domized, placebo-controlled, between-subjects design, the participants
received either a single dose of 0.5 mg of testosterone (n = 26; testos-
terone was suspended in 0.5 ml of solution with 0.5 mg of hydroxypropyl-
b-cyclodextrin, 0.005 ml of 96% ethanol, and distilled water) or a matched
placebo (n = 28) containing the same ingredients except for the testosterone.
Both liquids were manufactured by the pharmacy of the Leiden Uni-
versity Medical Center in accordance with good manufacturing prac-
tice. The pharmacy was also in charge of blinding and randomization,
and the participants were not able to detect which substance they had
received above chance level (54% were correct; c2 = 0.30, P = 0.68).
About 30 min after arrival in the laboratory between 10:00 a.m. and
12:30 p.m., the participants self-administered the liquid under the su-
pervision of the experimenter. Specifically, they held the solution under
their tongue for 60 s before swallowing it. This procedure entails the
direct absorption of testosterone into the bloodstream, leading to a sharp
increase in plasma testosterone15minafter administration (23). Previous
research has demonstrated that behavioral and physiological effects
are measureable about 4 to 6 hours after testosterone intake (19), which
has been further confirmed in investigations of social-emotional behav-
iors in young females [for example, (18, 24–28)].
Subsequent to substance administration and before testosterone ef-
fects were expected to emerge, the participants filled out several per-
sonality questionnaires to characterize and compare the subject sample
(see the Supplementary Materials). Additionally, the participants re-
ceived instructions and training for the experimental tasks. For the
remaining time, they were allowed to do schoolwork or reading in
the waiting room, but social interaction was restricted. Four hours la-
ter, the participants were positioned in the MRI for an anatomical
scan (6 min), the social AA task (20 to 25 min), and another exper-
imental task (20 min; reported elsewhere). Thus, the data reported
here were obtained in the afternoon, that is, after 1:30 p.m., between
4 and 4.5 hours after testosterone administration. After the MRI ses-
sion, the participants completed several exit questionnaires, for exam-
ple, assessing their belief on whether they received testosterone or
placebo, and were debriefed. Saliva samples for cortisol and testoster-
one analyses were obtained at baseline (upon arrival in the laboratory)
and 30 min, 3 hours, and 5 hours after administration. The total dura-
tion of the experimental session was 6.5 hours.
AA task. In this fMRI-adapted RT task (16, 29), the participants
had to respond to visually presented emotional facial expressions
by either pulling a joystick toward their body (approach move-
ment) or pushing it away from their body (avoidance movement).
Stimuli were taken from several databases (30–33) and contained
two affective expressions (happy and angry) for each of the 36
models (18 females). The faces were trimmed to exclude influences
from hair and nonfacial contours (34) and matched for brightness
and contrast values.
The task comprised of 16 blocks with 12 trials per block in which
the participants had to categorize the affective expression. At the start
of each block, participants received written instructions regarding the
stimulus-response mapping, that is, either pulling the joystick upon
seeing a happy face and pushing for an angry face (affect-congruent
trials), or pushing for a happy face and pulling for an angry face (affect-
incongruent trials). This operationalization is in line with a recent meta-
analysis (35) demonstrating strongest effects for the explicit evaluation
of the affective value of stimuli (happy/angry). The mapping changed
after each block and its order was counterbalanced across participants.
Blocks were separated by an interblock interval of 21 to 24 s.
Each trial started with a blank screen for 300 ms. Subsequently, the
stimulus was presented in grayscale against a black background for
100 ms, followed by the participants’ response and a variable intertrial
interval (ITI; blank screen; 2 to 4 s). Following previous studies using
the AA task during fMRI (15–17), images were presented without a
“zooming” feature to avoid neural confounds related to an image
moving toward or away from the participants as well as mere exposure
effects.
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Valid responses were defined as joystick displacements of at least
80% along the sagittal plane occurring within 2 s after stimulus pre-
sentation. After their response, the participants had to move the joy-
stick back to the starting position (the central area of 20% on the sagittal
plane) before the end of the ITI. The participants received feedback
in the case of kinematically invalid responses (“You did not move
the joystick far enough.”; “Please return the joystick to the starting
position.”).
Stimuli were projected (visual angle, 4° × 6°) at the center of a
screen that was viewed via a mirror above the participants’ head. An
MR-compatible joystick (Fiber Optic Joystick, Current Designs; sam-
pling rate, 550 Hz) was positioned on the abdomen of the participants.
Presentation of stimuli and acquisition of responses were controlled by
a PC running Presentation software version 13.
Image acquisition. Images were acquired on a 1.5-T MRI scanner
(Avanto, Siemens Medical Systems) equipped with an eight-channel
head coil using a multiecho GRAPPA (GeneRalized Autocalibrating
Partially Parallel Acquisitions) sequence (36) [repetition time (TR),
2.14 ms; echo times (TEs), 9.4/21/33/44/56 ms; 34 transversal slices;
ascending acquisition; distance factor, 17%; effective voxel size, 3.3 ×
3.3 × 3.5 mm; field of view (FoV), 212 mm]. Anatomical images were
acquired using an MP_RAGE (magnetization-prepared rapid gradient-
echo) sequence (TR, 2250 ms; TE, 2.95 ms; 176 sagittal slices; voxel size,
1.0 × 1.0 × 1.0 mm; FoV, 256 mm).
Salivary hormone measures. Saliva was collected in 15-ml Cellstar
tubes (Greiner Bio-One) and stored at −25°C. Samples were analyzed
in duplicate for testosterone and cortisol, and the average was used in
subsequent analyses. Hormone concentrations were measured using
Luminescence Immunoassays (Immuno-Biological Laboratories GmbH).
The average intra-assay and interassay coefficients were between 4.8
and 7.8% for cortisol and 6.5 and 8.6% for testosterone.
Statistical analyses
Behavioral data. Trials with incorrect or no responses were clas-
sified as errors and analyzed separately. The error rate was calculated
per level of the two experimental factors per participant. When the
error rate in a block was above chance level, the whole block was ex-
cluded because it can be expected that the participants misunderstood
the instructions for that specific block (15–17). In total, 11.1% of trials
were excluded (of which 5.3% were errors, 0.9% were omissions, 0.4%
were excluded because of block errors, and 4.5% were anomalous kin-
ematic responses), with 9.98% excluded in the testosterone group and
11.59% in the placebo group, which is comparable to previous studies
with this paradigm (16, 17). Groups did not differ in the number of
excluded trials (t52 = 0.95, P = 0.35).
The time from stimulus presentation until movement onset cor-
responds to movement initiation, and the time from movement onset
until reaching the target position of the joystick reflects the move-
ment duration. The RT was defined as the time from stimulus pre-
sentation until attainment of the target position. Trials with amovement
duration shorter than 400 ms and those with a movement initiation
outside the range of 100 to 1500 ms or exceeding 3 SDs from the
subject-specific mean were excluded. Median RTs were calculated for
each level of the two experimental factors (Emotion and Movement)
and subjected to a repeated-measures ANOVA, with the within-subject
factors Emotion (angry and happy) and Movement (approach and
avoid) and the between-subjects factor Substance (testosterone and
placebo).
Independent t tests were used to assess group difference on base-
line levels of testosterone and cortisol. The standardized testosterone
and cortisol levels from the first saliva measurement were included in
the ANOVAs as covariates. For all analyses, the a level was set at P <
0.05. For the ANOVAs, within-subject effects with Greenhouse-Geisser
correction are reported. Statistical testing was performed with the Sta-
tistical Package for the Social Sciences (IBM SPSS 19).
Imaging data. Statistical parametric mapping (SPM8) was used
for preprocessing and analyzing the imaging data. To allow for
magnetic saturation, the first four volumes of each data set were dis-
carded. Using a least-squares approach with six rigid body transfor-
mation parameters (translations and rotations), motion parameters were
estimated on the basis of the MR images of the first echo (TE, 9.4 s) (16).
After applying the motion correction parameters to the images from
all echoes, single MR volumes were obtained by combining the five
echo images based on an optimized echo weighting method (36). Sub-
sequently, images were slice time–corrected, and the anatomical scan
was co-registered with the mean of the functional images. Normaliza-
tion into Montreal Neurological Institute space was based on a segmen-
tation algorithm (37). Images were resampled at a voxel size of 2 × 2 ×
2 mm and spatially smoothed using an 8-mm full-width-at-half-
maximum Gaussian kernel.
The general linear model was applied to the time series of each
participant. For this event-related design, trials were averaged separately
for each condition, yielding the following four task-relevant regressors:
approach-happy, avoid-happy, approach-angry, and avoid-angry. Two
additional regressors were derived from modeling missed responses and
periods where instructions were presented. Events were isolated by con-
volving vectors of stimulus onset times and movement initiation as du-
ration with the canonical hemodynamic response function. Potentially
confounding residual head movement effects were modeled with regres-
sors based on the original, squared, cubic, first-order, and second-order
derivatives of the movement parameters (38) as well as signal intensities
of white matter, cerebrospinal fluid, and the portion of the MR image
outside the skull. Finally, images were high- pass–filtered at 128 s, and
an autoregressive AR(1) model was used to account for serial correla-
tions in fMRI time series.
Analyses on the group level were performed by subjecting the four
task-relevant contrast images per participant (approach-happy, avoid-happy,
approach-angry, and avoid-angry) to a random-effects multiple regression
analysis (Substance × Emotion × Movement). Standardized endogenous tes-
tosterone and cortisol levels (obtained from the first saliva sample) were
included as covariates, resulting in another 16 regressors [as in, for
example, (16)]. The following effects were considered.
First, to address our main question of whether testosterone admin-
istration modulates amygdala reactivity to angry faces, we performed
a ROI analysis on the amygdala (comprising the basolateral, corticome-
dial, and superficial subregions bilaterally) based on cytoarchitectonic
probability maps implemented in the SPM toolbox (39, 40). Here, we
tested for the three-way interactions of Substance × Emotion × Move-
ment. To understand potential interaction effects, parameter estimates
were extracted from the activation cluster within the amygdala and
subjected to statistical analyses in SPSS with a set at P < 0.05.
Second, to examine the involvement of the aPFC in motivationally
incongruent responses irrespective of hormonal modulations, the con-
gruency effect (Emotion × Movement) was assessed for both groups
together and separately with an ROI based on Brodmann area 10,
which has previously been implicated during this task (15–17). In other
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words, activation during affect-incongruent trials (approach-angry
and avoid-happy) was compared to that on affect-congruent trials
(approach-happy and avoid-angry). The reported activations from the
ROI analyses are corrected for multiple comparisons over the search
volume using FWE (P < 0.05) (41).
An additional psychophysiological interaction (PPI) analysis was
conducted to explore whether there was a task- and testosterone-dependent
modulation in connectivity between the amygdala and right aPFC dur-
ing incongruent versus congruent trials, using an 8-mm sphere around
the right aPFC (30 62 −4; see Results) as a seed region. Within this
region, voxels showing task-related activity (P < 0.01, uncorrected),
assessed by an F-contrast of task-related regressors (approach-happy,
avoid-happy, approach-angry, and avoid-angry), were included. Partic-
ipants who did not show any voxels with significant task-related ac-
tivity in this region were excluded from the PPI analysis (n = 5, of
which n = 2 in the testosterone group and n = 3 in the placebo group).
Subject-specific contrast images of the remaining 49 participants de-
scribing the PPI between the time course of the aPFC volume of in-
terest (VOI) and the time course of the incongruent versus congruent
trials were generated. Group inferences were based on a multiple regres-
sion analysis with the participant-specific contrast images and their en-
dogenous testosterone and cortisol levels (obtained from the first saliva
sample) as regressors. Apart from whole-brain analyses, we tested for
substance differences within an amygdala VOI that was created on
the basis of the activation identified in the ROI analyses of approach
versus avoidance of angry faces (see Results) using a small-volume
correction (41) (PFWE < 0.05).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/
full/1/5/e1400074/DC1
Fig. S1. Contrast estimates for the left amygdala cluster during approach and avoidance of
angry faces in each condition.
Table S1. Means (SE) of questionnaire scores.
Methods and Results. Motivation-specific effects of testosterone during threat approach and
avoidance within the left amygdala.
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